Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019404 | 1.00 | GSK3B (0.48) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL2161457 | 1.00 | GSK3B (0.48) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL9856420 | 0.99 | GSK3B (0.47) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL6887049 | 0.90 | GSK3B (0.48) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL15667008 | 0.90 | GSK3B (0.39) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL6887652 | 0.87 | GSK3B (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL8540328 | 0.86 | GSK3B (0.49) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL6889230 | 0.86 | GSK3B (0.43) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL5697577 | 0.85 | GSK3B (0.47) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL4286250 | 0.85 | GSK3B (0.47) | GSK3BTSHRADKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665856-A2 | DNA COMPOSITIONS COMPRISING MODIFIED CYTOSINE | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20240293582-A1 | DNA COMPOSITIONS COMPRISING MODIFIED CYTOSINE | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2024-09-05 | — | — | US | claimed |
| WO-2024173836-A2 | DNA COMPOSITIONS COMPRISING MODIFIED CYTOSINE | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2024-08-22 | — | — | WO | claimed |
| CN-112961911-B | Quantitative analysis method of 5-hydroxymethylcytosine in DNA | 河北大学 | 2022-11-18 | — | — | CN | claimed |
| CN-112646860-B | DNA methylation targeted enrichment method and application thereof | 中国医学科学院北京协和医院 | 2022-10-11 | — | — | CN | claimed |
| EP-4041919-A1 | COMPOSITIONS AND METHODS FOR ANALYZING CELL-FREE DNA IN METHYLATION PARTITIONING ASSAYS | Guardant Health, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| US-20210371910-A1 | DETECTION OF DNA HYDROXYMETHYLATION | ZYMO RES CORPORATION (US) | 2021-12-02 | — | — | US | claimed |
| US-20160138079-A1 | Mapping Cytosine Modifications | NEW ENGLAND BIOLABS, INC. (US) | 2016-05-19 | — | — | US | claimed |
| WO-2014074450-A1 | MAPPING CYTOSINE MODIFICATIONS | NEW ENGLAND BIOLABS, INC. (US) | 2014-05-15 | — | — | WO | claimed |
| US-20260146294-A1 | METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTION | GUARDANT HEALTH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260139324-A1 | CLASSIFICATION OF BREAST TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | GUARDANT HEALTH INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107204-A1 | METHODS FOR ANALYZING LOW-DEPTH GENOME SEQUENCING DATA TO DETECT MINIMAL RESIDUAL DISEASE | GUARDANT HEALTH, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260139325-A1 | CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | GUARDANT HEALTH INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4744054-A1 | CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | Guardant Health, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20120208193-A1 | DETECTING METHYLATION IN A SUBPOPULATION OF GENOMIC DNA | BIO-RAD LABORATORIES, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120064521-A1 | DETECTION OF DNA HYDROXYMETHYLATION | ZYMO RESEARCH CORPORATION | 2012-03-15 | — | — | US | disclosed |
| US-20110183320-A1 | CLASSIFICATION OF NUCLEIC ACID TEMPLATES | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| EP-0133044-B1 | STABILISING FOREIGN PROTEINS, AND PLASMIDS FOR USE THEREIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1990-11-07 | — | — | EP | disclosed |
| US-4845031-A | Recombinant DNA process for producing useful polypeptides | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0133044-A1 | Stabilising foreign proteins, and plasmids for use therein | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146294-A1 | METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTION | NSUN2, NOP2, ADAR | GSK3B 4775/4885TSHR 3458/4885ADK 1600/4885 |
| US-20240293582-A1 | DNA COMPOSITIONS COMPRISING MODIFIED CYTOSINE | DNASE1, UNG, DNMT1 | GSK3B 3353/4885TSHR 3963/4885ADK 204/4885 |
| US-20260139325-A1 | CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | BRCA1, DNMT3A, DNMT1 | GSK3B 209/4885TSHR 1799/4885ADK 3604/4885 |
| US-20260139324-A1 | CLASSIFICATION OF BREAST TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | BRCA1, DNMT3A, DNMT3B | GSK3B 381/4885TSHR 1317/4885ADK 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.